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Edited by Richard MaraisAbstract All ligands of the epidermal growth factor receptor
(EGFR), which has important roles in development and disease,
are made as transmembrane precursors. Proteolytic processing
by ADAMs (a disintegrin and metalloprotease) regulates the bio-
availability of several EGFR-ligands, yet little is known about
the enzyme responsible for processing the recently identiﬁed
EGFR ligand, epigen. Here we show that ectodomain shedding
of epigen requires ADAM17, which can be stimulated by phorbol
esters, phosphatase inhibitors and calcium inﬂux. These results
suggest that ADAM17 might be a good target to block the re-
lease of bioactive epigen, a highly mitogenic ligand of the EGFR
which has been implicated in wound healing and cancer.
 2006 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Epigen is a recently identiﬁed ligand of the epidermal growth
receptor (EGFR, ErbB1), and belongs to a group of function-
ally and structurally similar growth factors that mediate cellu-
lar responses ranging from cell survival to proliferation and
migration [6,29]. Epigen was ﬁrst isolated from a mouse kerat-
inocyte cDNA library due to its homology to the EGFR-li-
gand epiregulin [25]. It shows 24–37% identity to other
EGFR ligands (EGF, TGFa, HB-EGF, amphiregulin, beta-
cellulin, epiregulin), and contains six spatially conserved cys-
teine residues that are characteristic of members of this
protein family [6]. The biological activity of recombinant epi-
gen is similar to that of other EGFR ligands. In epithelial cells,
it stimulates phosphorylation of the EGFR and downstream
signaling molecules such as the mitogen activated protein ki-
nase (MAPK), and it promotes cell proliferation in a dose-
dependent manner [25].
Despite its relatively low aﬃnity for the EGFR, epigen has
an increased mitogenic potential compared to other EGFR li-
gands. When EGFR expressing cells were treated with equal*Corresponding author. Address: Arthritis and Tissue Degeneration
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doi:10.1016/j.febslet.2006.11.074concentrations of EGF, TGFa or epigen, epigen was found
to be the most potent mitogen [12]. Epigen eﬀectively activates
signaling via an EGFR-homodimer or through a heterodimer
between EGFR and ErbB2 [12]. Epigen is widely expressed in
a variety of mouse tissues, especially in multiple developing
structures in the embryo, such as developing tongue papillae,
the dorsal root ganglion and the inner and outer root sheath
of hair follicles, all of which are regions of active proliferation
[12]. Moreover, epigen expression is also observed in invasive
adenocarcinomas of the breast and prostate in humans [12].
All seven EGFR ligands described to date (TGFa, HB-EGF,
amphiregulin, epiregulin, EGF, betacellulin and epigen) are
synthesized as membrane-anchored precursors that are subse-
quently released from the cell surface by proteolysis [6]. This
proteolytic processing is considered to be a key regulatory step
controlling the bioavailability of soluble EGFR-ligands, and
thus signaling via the EGFR [18] (for a recent review, see
[2]). Membrane-anchored metalloprotease-disintegrin proteins
(ADAMs, a disintegrin and metalloprotease) have been impli-
cated in the ectodomain shedding of six out of the seven
currently known EGFR ligands [3,18,21,26]. Speciﬁcally,
ADAM17 has been shown to have a major role in processing
of TGFa, HB-EGF, amphiregulin and epiregulin, and
ADAM10 is a major sheddase of EGF and betacellulin
16,18,21,22,26]. However, little is known about the enzyme(s)
responsible for the proteolytic release of epigen. In this study,
we show that the ectodomain of epigen is released from the cell
membrane constitutively at low levels, and that its shedding
can be highly upregulated by phorbol esters, calcium iono-
phores and tyrosine phosphatase inhibitors. Moreover, we
provide evidence for a major role of ADAM17 in stimulated
shedding of epigen. These results uncover a ﬁfth EGFR-ligand
as a substrate for ADAM17, an enzyme with an essential role
in activating the EGFR during mouse development [18].2. Materials and methods
An expression vector encoding the alkaline phosphatase (AP)-tagged
epigen was constructed by inserting a partial cDNA for mouse epigen,
which encoded for the EGF repeat, the juxtamembrane domain
containing the putative cleavage site, transmembrane domain and
cytoplasmic domain, into the 3 0 end of human placental alkaline
phosphatase in the CMV-based vector APtag-5 (Genhunter Corp.).
The junction between AP and epigen was placed in frame at Leu 53
at the N-terminus of the EGF repeat of mouse epigen, which has
152 amino acid residues. The epigen-AP fusion construct also contains
a C-terminal Myc and His tag attached to the cytoplamic domain of
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type E13.5 mouse embryos and cultured as described previously [28],
and Adam17/ mEFs, which have also been described previously
[19] were transfected with a cDNA vector encoding the AP-epigen fu-
sion protein with LipofectAMINE (Invitrogen). Fresh Opti-MEM
(Invitrogen) medium was added the next day, conditioned for 1 h,
and then replaced with fresh medium containing one of the following:
20 ng/ml PMA (Sigma), 2 lM ionomycin, 100 lM pervanadate, 1 lM
batimastat (BB94, provided by D. Becherer, GlaxoSmithKline, Re-
search Triangle Park, NC), 1–10 lM GI254023X or GW280164X
[13]. The conditioned medium containing inhibitors or activators of
ectodomain shedding was collected after 1 h. Evaluation of AP activity
by SDS–PAGE or spectrophotometry was performed as described pre-
viously [20].CT cytosol
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Fig. 1. Constitutive and stimulated shedding of epigen from COS-7
cells. (a) Diagram of the alkaline phosphatase (AP) reporter detection
system used to monitor epigen shedding from COS-7 cells. An AP
moiety was fused in frame N-terminal to the EGF-repeat (EC,
extracellular domain) of mouse epigen. Proteolytic cleavage in the
juxtamembrane (JM) region releases the epigen-AP fusion protein into
the culture supernatant. The released epigen-AP can be detected by
SDS-PAGE (b) or through spectrophotometry (c for details, see
materials and methods, and reference [20]). (b) Epigen-AP is consti-
tutively released at low levels from transiently transfected COS-7 cells
(lanes 1,3). Release of epigen-AP from COS-7 cells was upregulated by
20 ng/ml PMA (lane 2) and blocked by the metalloprotease inhibitor
BB94 at a concentration of 1 lM (lane 4) (c) Upregulation of epigen-
AP release from COS-7 cells upon PMA treatment is detected by a
spectrophotometric assay for AP activity [20]. PMA stimulated
shedding of epigen can be abolished by BB94 which also inhibits its
constitutive processing. n = 6, error bars: standard deviation.3. Results
In order to study the ectodomain shedding of epigen from
cells, an alkaline phosphatase (AP) moiety was attached to
the amino terminus of the EGF repeat of epigen (Fig. 1a). A
similar approach has previously been used to study ectodomain
shedding of other EGFR ligands [21,28]. The main advantage
of adding an AP tag is that it facilitates the detection and quan-
titation of shed forms of epigen. Moreover, previous studies
have shown that the AP tag did not aﬀect which enzyme was
responsible for shedding other EGFR-ligands, since both the
AP-tagged forms of TGFa or HB-EGF and untagged wild type
forms of these EGFR-ligands were shed by ADAM17
[11,18,21,26]. When COS-7 cells were transfected with AP-
tagged epigen, low levels of constitutive shedding into the
culture supernatant were observed (Fig. 1b, lanes 1 and 3).
Constitutive release of epigen was strongly induced after addi-
tion of the phorbol ester PMA (Fig. 1b, lane 2 and Fig. 1c).
Both the constitutive and the PMA-regulated components of
epigen-AP shedding could be eﬀectively inhibited by the
hydroxamate-type metalloprotease inhibitor BB94 (batimastat,
Fig. 1b, lane 4 and Fig. 1c) suggesting that a metalloprotease,
most likely an ADAM, is involved in this process. Speciﬁcally,
the strong stimulation of epigen shedding by PMA is reminis-
cent of ADAM17 mediated ectodomain shedding of four other
EGFR ligands, TGFa, HB-EGF, amphiregulin and epiregulin,
as well as of other ADAM17-substrates such as TNFa [21,30].
Essentially identical results were obtained when these experi-
ments were repeated in CHO cells (data not shown).
To further characterize the epigen sheddase in COS-7 cells,
we tested how two distinct hydroxamate-type metalloprotease
inhibitors with some selectivity against ADAM10 or
ADAM17 aﬀected epigen shedding in these cells. The hydroxa-
mate GI254023X (GI) had previously been shown to block
ADAM10-mediated constitutive release of IL6R, CX3CL1
and CXCL16 at concentrations between 1 and 10 lM, while
compound GW280264X (GW) blocked PMA induced cleav-
age mediated by ADAM17 at these concentrations [13]. Con-
stitutive shedding of epigen from COS7 cells was not aﬀected
by 1 lM GI, whereas it was eﬀectively blocked by GW at con-
centrations as low as 1 lM (Fig. 2). GI had a partial inhibitory
eﬀect on epigen shedding at 5 lM, and increasing inhibition
was observed at higher concentrations of GI (7.5 lM and
10 lM). However, at all concentrations tested here (1–
10 lM), GW inhibited epigen shedding more eﬃciently than
GI. This inhibition proﬁle suggested that ADAM17, but not
ADAM10, was responsible for epigen shedding. The increased
shedding of epigen following stimulation by PMA was alsoconsistent with a role for ADAM17 in this process, since
ADAM17 is considered to be one of the principal enzymes that
responds to short-term stimulation with PMA (<1 h) [7,21].
In order to directly test whether ADAM17 is required for
epigen shedding, we compared epigen processing in response
to various stimuli in wild type mouse embryonic ﬁbroblasts
(mEF) versus mouse embryonic ﬁbroblasts derived from
adam17/ knockout mice (E2 cells) [18,19]. Similar to
COS-7 cells, the epigen ectodomain was constitutively released
from wild type mEFs at low levels, and this constitutive release
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Fig. 2. Inhibition of constitutive release of epigen from COS-7 cells by
the ADAM10-selective inhibitor GI254023X (GI), or the inhibitor
GW280264X (GW), which has a similar IC50 towards ADAM10 and
ADAM17 in cell based assays [8,13]. Constitutive shedding of epigen is
set to 100%. At 1 lM, GW eﬀectively inhibits epigen shedding, whereas
GI does not, suggesting that this process is mediated by ADAM17.
n = 3, error bars: standard deviation.
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tion, the phosphatase inhibitor pervanadate (PV) stimulated
epigen shedding more than 12-fold compared to constitutive
release in wild type cells, and the calcium ionophore ionomycin
(IO) stimulated epigen shedding nearly 4-fold (Fig. 3). The in-
crease in epigen shedding following stimulation with PMA, PV
and IO was almost completely abolished in adam17/ E2
cells (Fig. 3). Shedding could be partially rescued by reintro-
duction of wild type ADAM17, but not of a catalytically inac-
tive mutant form of ADAM17 (data not shown). These results0
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Fig. 3. Epigen shedding from mouse embryonic ﬁbroblasts following
stimulation with PMA, pervanadate (PV) or ionomycin (IO) requires
ADAM17. Transiently transfected wild type and adam17/ mEFs
were stimulated with PMA, PV or IO for 1 h and levels of epigen-AP
released into culture media were compared. Similar to COS-7 cells
shown in Fig. 1, mEFs release high amounts of soluble epigen-AP
following PMA stimulation, and this release can be blocked by 1 lM
BB94. The increased shedding of epigen following addition of PMA,
IO or PV is almost completely abolished in adam17/ cells. n P 4,
error bars: standard deviation.demonstrate that ADAM17 is the major sheddase for epigen in
mEF cells, corroborating the results obtained with the
hydroxamates GI and GW in COS7 cells. In addition, no de-
fect in the stimulation of epigen shedding by PMA, ionomycin
and pervanadate was observed in adam10/ mEFs compared
to their adam10+/ counterparts, suggesting that ADAM10 is
not required for epigen shedding (data not shown).4. Discussion
Signaling via the EGFR (ErbB1) has essential roles in devel-
oping embryos and in adults [6,29]. In addition, dysregulation
of the EGFR signaling network has been tied to tumor forma-
tion and invasion [5]. Release of soluble EGFR ligands from
their membrane anchored precursors is considered to be a
key step in initiating the EGFR-signaling; therefore enzymes
mediating this release are potential drug targets for treatment
of EGFR-dependent tumors [1,2,9,23,31].
Here we show that shedding of epigen, an EGFR-ligand
with high mitogenic potential, can be stimulated by the phor-
bol ester PMA, the phosphatase inhibitor pervanadate and the
calcium ionophore ionomycin. Moreover, we demonstrate that
shedding of epigen induced by these three stimuli requires
ADAM17. These results extend our previous analysis of the
role of ADAMs in shedding EGFR-ligands, and show that
all seven EGFR ligands identiﬁed to date are substrates of
either ADAM10 or ADAM17. ADAM17 is thought to be
essential for activating the EGFR via shedding of several of
its ligands, since mice lacking ADAM17 [18] resemble mice
lacking TGFa [15], HB-EGF [10,11] or amphiregulin [14], or
the EGFR [17,24,27]. It will now be interesting to evaluate
the phenotype of animals lacking epigen in relation to egfr/
 or adam17/ animals as epigen is widely expressed in
the embryo in a variety of developing structures 12,25]. More-
over, whereas previous studies have demonstrated that
ADAM17 is stimulated by phorbol esters such as PMA, and
by the phosphatase inhibitor pervanadate [4,21,30], this study
is the ﬁrst, to our knowledge, to demonstrate that ADAM17
also responds to calcium inﬂux, since ionomycin induced shed-
ding of epigen is abolished in the absence of ADAM17.
In summary, this study shows that ectodomain shedding of
the recently identiﬁed EGFR ligand, epigen, is mediated by
ADAM17. Identiﬁcation of the epigen sheddase may have
important implications for cancer treatment since soluble epi-
gen, like other EGFR ligands, induces cell proliferation and
migration, two major processes that are dysregulated in tumor
cells. Since ectodomain shedding of EGFR-ligands is critical
for their functional activation, the identiﬁcation of ADAM17
as major sheddase of epigen further expands the potential of
ADAM17 as a novel anti-cancer drug target.
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